GHRP-2 (pralmorelin) is a synthetic six-amino-acid peptide that acts on the ghrelin receptor and triggers growth hormone release. It is not FDA approved. The FDA lists it among bulk substances that may present significant safety risks in compounding.
Also known as: Pralmorelin, KP-102.
Powder vials are usually labeled 5 mg or 10 mg.
Water and syringe-unit charts by vial size: 5 mg · 10 mg
Here is the math for a 5 mg vial mixed with 2 mL of bacteriostatic water, drawing 100 mcg with a U-100 insulin syringe (1 mL = 100 units).
5 mg ÷ 2 mL = 2.5 mg/mL100 mcg ÷ 2.5 mg/mL = 0.04 mL0.04 mL × 100 = 4 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 50 mcg | 0.02 mL | 2 units |
| 100 mcg | 0.04 mL | 4 units |
| 200 mcg | 0.08 mL | 8 units |
Adding more water doesn't change how much GHRP-2 is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 3 mL | 1.67 mg/mL | 0.06 mL | 6 units |
| 5 mL | 1 mg/mL | 0.1 mL | 10 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
GHRP-2 raises growth hormone strongly in healthy people, which is why it was developed in Japan as a diagnostic test for growth hormone deficiency. In a small study of 7 healthy men, an infusion under the skin raised growth hormone and they ate about 36% more at a buffet meal than on saline.
The FDA placed GHRP-2 (injectable and nasal) in category 2 for 503B outsourcing facilities in September 2023. It cites a risk of immune reactions from aggregation and peptide impurities, and reports of rising insulin needs, deaths in critically ill study subjects, infection and pancreatitis, though it says causality is not established.
We could not find a published human half-life for this compound. Figures quoted online usually come from animal or cell studies, so we do not list one here.